Pharmaceutical Executive June 30, 2020
Michael Wong speaks to retired pharma exec Wayne Yetter (founding CEO of AstraMerck and former CEO of Novartis US) and Renold (Ren) Capocasale, CEO of FlowMetric Life Sciences, about making the transition from a Fortune 500 firm to a startup.
Michael Wong: As CEO of the start-up, AstraMerck Group, which eventually evolved into today’s AstraZeneca, what was the secret sauce to not only build a sustainable organization (on which a Harvard Business School case study was written),[1] but also to create career opportunities for your direct reports and other employees?[2]
Wayne YetterWayne Yetter: Back in 1992 after some initial planning for the AstraMerck start-up, there were approximately twenty-five employees who accepted the challenge to build a new pharmaceutical company....
Today's Sponsors
Today's Sponsor